Presentations by Program

Search by Program

In vitro Antibacterial Activity of Sulbactam Durlobactam (ETX2514) against 121 Recent Acinetobacter baumannii Isolates from Patients in India

Alita Miller, ID Week 2019

In vitro Antibacterial Activity and in vivo Efficacy of Sulbactam-Durlobactam (ETX2514) against Pathogenic Burkholderia Species

Alita Miller, ID Week 2019

Resistance to Sulbactam Durlobactam in Clinical Isolates of Acinetobacter baumannii is Rare and Maps to PBP3

Samir Moussa

Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection For the Novel β lactamase Inhibitor ETX2514 in Combination with Sulbactam Against Acinetobacter baumannii calcoaceticus Complex (ABC)

John O'Donnell, ASM Microbe 2019

The Novel β-lactamase Inhibitor ETX2514 Restores Sulbactam Activity against Recent, Globally Diverse Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

Sarah McLeod, ASM Microbe 2019

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analyses of ETX2514SUL to Support Dosing Regimens in Patients with Varying Renal Function

N.J. Onufrak (ICPD), ECCMID 2019

Restoration of Sulbactam Activity by the Novel β-lactamase Inhibitor ETX2514 Against Recent Global Clinical Isolates of Acinetobacter baumanniicalcoaceticusComplex Isolates

Sarah McLeod, ECCMID 2019

The Susceptibility of Sulbactam/ETX2514 and Comparators to Global Isolates of Acinetobacter baumannii

Harald Seifert (University of Cologne), ECCMID 2019

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Suba Srinivasan, ECCMID 2019

ETX2514SUL (sulbactam/ETX2514) For The Treatment of Acinetobactor Baumannii Infections

Robin Isaacs, ID Week 2018